A Pan-Cancer Analysis Reveals CLEC5A as a Biomarker for Cancer Immunity and Prognosis.
Chen R, Wu W, Chen SY, Liu ZZ, Wen ZP, Yu J, Zhang LB, Liu Z, Zhang J, Luo P, Zeng WJ, Cheng Q.
Chen R, et al.
Front Immunol. 2022 Aug 1;13:831542. doi: 10.3389/fimmu.2022.831542. eCollection 2022.
Front Immunol. 2022.
PMID: 35979347
Free PMC article.
The drug sensitivity analysis screens out potential therapeutic agents associated with CLEC5A expression, including FR-180204, Tivozanib, OSI-930, Linifanib, AC220, VNLG/124, Bexarotene, omacetaxine mepesuccinate, narciclasine, leptomycin B, PHA-793887, LRRK2-IN-1, …
The drug sensitivity analysis screens out potential therapeutic agents associated with CLEC5A expression, including FR-180204, …